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ABSTRACT
Objective: The current research work is intended to formulate propranolol HCl (PLH) as orally disintegrating tablet (ODT). It is also intending to check 
the superiority in a combination of superdisintegrants and effervescent mixture than the use of superdisintegrants alone by a direct compression 
technique. To fasten the onset of action and thereby enhancing the bioavailability of PLH in comparison to its conventional tablets.
Methods: Standard calibration curve of PLH was obtained in pH 6.8 phosphate buffer by spectrophotometric method, drug-excipient compatibility 
studies were carried by Fourier transform infrared (FT-IR) studies. All the formulations were evaluated for pre and postcompression studies. 
Accelerated stability studies were carried out up to 6 months for the optimized formulation, EF3. 
Results and Discussion: Superdisintegrants used in the study are compatible with PLH. Pre- and post-compression parameters were within the 
acceptable limits for all formulations. In vitro dissolution kinetic studies indicate the release of PLH from ODT increases as the concentration of 
superdisintegrants as well as the ratio of citric acid: NaHCO3 of effervescent mixture increases. Formulations with an effervescent mixture are having 
rapid disintegration and dissolution rate when compared to the formulations with superdisintegrants alone. The order of superdisintegrants in 
enhancing the dissolution rate of PLH is crospovidone (CPV) > croscarmellose sodium (CCS) > sodium starch glycolate (SSG). Formulation, EF3 (10% 
CPV and 1:3, citric acid: NaHCO3 ratio, respectively) had the highest dissolution efficiency at 10 minutes (DE10=82.74%); the first order dissolution 
rate constant (K1=0.141/minutes) with a regression coefficient (r2=0.974) and lesser time for 90% of drug release (t90=4 minutes), was considered as 
the optimal ODT in this study. Formulation EF3, passed the test for stability.
Conclusion: Hence, an effective PLH ODT was formulated by the direct compression technique with disintegration by combination of superdisintegrants 
and effervescent mixture, will fasten the onset of action and enhances the bioavailability of PLH in comparison to its conventional tablets.
Keywords: Propranolol HCl, Orally disintegrating tablet, Sodium starch glycolate, Croscarmellose sodium, Crospovidone, Direct compression, In vitro 
dissolution studies.
INTRODUCTION
The most preferred route of administration of dosage forms is oral route, 
due to its potential advantages such as ease of administration, convenient 
dosing, self-medication, no pain, and patient compliance. Hence, tablets 
and capsules are the most popular dosage forms [1]. However, the 
important drawback of these dosage forms is dysplasia [2]. The above-
mentioned problem can be solved by developing a fast disintegrating/
dissolving drug delivery, i.e., oral disintegrating/dissolving tablet, 
disintegrates and dissolves rapidly in the saliva, Within a few seconds 
without the need of drinking water or chewing [3]. In pharmaceutical 
sciences, disintegration usually means the process by which a solid 
dosage form breaks up when it comes in contact with aqueous 
medium. This promotes the rapid release of drug and faster absorption 
too [4]. A rapid disintegration process is the prerequisite for a good 
bioavailability [5]. Orally disintegrating tablets (ODT) provides ease of 
administration, immediate action, convenient dosing, self-medication, 
no pain, and increases patient compliance [6]. The medications of fast-
acting, compliance critical, and pediatrics are commonly suitable for 
ODT [7]. Propranolol HCl (PLH) is a nonselective beta blocker, which 
blocks the action of epinephrine and norepinephrine on both β1- and 
β2-adrenergic receptors. It has little intrinsic sympathomimetic activity 
but has strong membrane stabilizing activity. It is mainly used in the 
treatment of hypertension, supraventricular, tachyarrhythmia, ventricular 
arrhythmias, pheochromocytoma, thyrotoxicosis, and vascular headache. 
PLH is highly lipophilic and is almost completely absorbed after oral 
administration. However, it undergoes high first-pass metabolism by 
the liver and on average, only about 25% of PLH reaches the systemic 
circulation [8]. Clinically, orotransmucosal drug delivery is reported 
to be the most promising alternative approach for enhancing the 
bioavailability and fastening the onset of action in comparison to its 
conventional tablets because it has the high blood supply, a very thin 
membrane barrier (190  µm), and an ability to bypass hepatic first-
pass metabolism [9]. The properties of PLH, like low molecular weight 
(295.81 g/mol); lesser oral dose (20-40 mg) and lesser biological half-
life (3-5 h), makes it an ideal candidate, to select for the formulation of 
ODT [10,11]. This study was aimed to optimize the type and concentration 
of superdisintegrant by taking batches with 6%, 8%, and 10% w/w of 
different superdisintegrants (crospovidone [CPV], croscarmellose sodium 
[CCS], and sodium starch glycolate [SSG] only); (i.e., batches from: DC1 to 
DC9) and to study the effect of the effervescent mixture in combination 
with superdisintegrants by taking batches with 10% w/w different 
superdisintegrants along with different ratios (1:1; 1:2, and 1:3) of citric 
acid: NaHCO3, respectively (i.e., batches from: EF1 to EF9).
MATERIALS AND METHODS
Materials
PLH, SSG, CCS (Ac-DI-Sol), CPV (polyplasdone XL-10), citric acid, sodium 
bicarbonate (NaHCO3), mannitol (PERLITOL-SD-200), aspartame, 
powder vanilla flavor, magnesium stearate, talc, and sodium lauryl 
sulfate (SLS) are received as gift samples from Richer Pharmaceuticals 
Ltd., Bengaluru, India. All the excipients used in the study are of 
pharmaceutical grade.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i3.16096
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Methods
Standard calibration curve of PLH in pH 6.8 phosphate buffer [9]
Was obtained at the λmax 279 nm using an ultraviolet (UV)-visible 
spectrophotometer (UV-1700, Shimadzu, Mumbai, India) and 
represented in (Fig. 1). Which was further used for drug release 
calculations of in vitro dissolution studies and assay.
Drug-excipient compatibility/Fourier transform infrared (FTIR) 
studies [10]
FTIR studies were performed on drug and drug: Superdisintegrants (1:1). 
The samples were appropriately diluted with dried KBr (2 mg sample in 
200 mg KBr) and crushed to make pellets under hydraulic pressure of 
600 kg and then the resulting pellets were subjected to analysis by an IR 
spectrophotometer (Shimadzu, FTIR 8700), in the region between 400 
and 4000/cm. FTIR spectra of pure PLH and drug: Superdisintegrants 
(1:1) samples were represented in Fig. 2.
Preparation of PLH ODT [9]
All the formulations were prepared by direct compression method by 
keeping the amount of PLH constant at 40 mg. The composition of other 
excipients is varied as mentioned in formulation tables (Tables 1 and 2). 
In these formulations SSG, CCS and CPV are used as superdisintegrants, 
mannitol as a directly compressible diluent, aspartame is an artificial 
sweetener, powder vanilla flavor as flavoring agent, magnesium 
stearate as a lubricant, talc as glidant, SLS as a surfactant solubility 
enhancer, citric acid, and NaHCO3 as effervescent mixture. PLH and 
all the other excipients excluding magnesium stearate and talc were 
co-sifted through Sieve No. #40 (ASTM), blended uniformly in a poly 
bag for 10 minutes and lubricated with Sieve No. # 60 (ASTM), passed 
magnesium stearate and talc and mixed in a poly bag for an additional 
2-3 minutes. Tablets were compressed on a tabulating machine (16 
station, Cadmach Pharma Machinery Pvt. Ltd., India) fitted with 
8 mm standard round punches with an average weight of 200 mg and 
hardness of 2-3 kg/cm2.
Precompression studies [12]
The directly compressible tablet blends were evaluated for 
precompression studies.
Angle of repose (θ)
Was determined by funnelling method. The blend was poured through 
the walls of a funnel, which was fixed at a position such that its lower 
tip was at a height of exactly 2 cm above hard surface. The blend was 
Fig. 1: Standard calibration curve of propranolol HCl in pH 6.8 
phosphate buffer
Fig. 2: Fourier transform infrared spectra of (a) propranolol HCl (PH), (b) PH+crospovidone, (c) PH+croscarmellose sodium and 
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poured till the time when the upper tip of the pile surface touched the 
lower tip of the funnel. The θ is calculated by the equation.
θ=tan−1 h/r (1)




A quantity of 2 g of blend from each formulation (previously lightly 
shaken to break any agglomerates formed) was introduced into a 10 mL 
measuring cylinder, and the volume is noted as bulk volume. The BD 
was calculated by the equation.
Bulk density=weight of powder/bulk volume (2)
Tapped density (TD)
After the determination of BD, the measuring cylinder was fitted with a 
TD apparatus. The tapped volume was measured by tapping the powder 
for 500 times. Later the tapping was done for another 750 times, and the 
tapped volume was noted (the difference between these two volumes 
should be <2%). If it is more than 2%, tapping is continued for another 
1250 times, and the constant tapped volume was noted. The TD was 
calculated by the equation.
Tapped density=weigh of powder/tapped volume (3)
Carr’s index (CI): The percentage of CI is calculated by the equation.
CI=(tapped density-bulk density)×100/tapped density (4)
Hausner’s ratio (HR): Is a number that correlates to the flowability of 
powder. It is calculated by the equation.
HR=tapped density/bulk density (5)
Precompression studies of all the formulations were carried out in 
triplicate; the consolidated results (mean±SD) were tabulated in 
Table 3.
Postcompression studies
Tablet weight variation [12]
An electronic balance (Mettler Toledo, 3-MS-S/MS-L, Switzerland) was 
used to accurately weigh the individual weight of 20 tablets which were 
randomly selected from each formulation. The (mean±SD) values were 
calculated.
Friability test [12]
The friability of the 20 tablets from each formulation was tested by 
a friabilator (ERWEKA, TAR 120, Germany) at a speed of 25 rpm for 
Table1: Formulation table of PH ODT with superdintegrents alone
%w/w superdisintegent 6% CPV 8% CPV 10% CPV 6% CCS 8% CCS 10% CCS 6% SSG 8% SSG 10% SSG
Ingredients* DF1 DF2 DF3 DF4 DF5 DF6 DF7 DF8 DF9
PH 40 40 40 40 40 40 40 40 40
CPV 12 16 20 - - - - - -
CCS - - - 12 16 20 - - -
SSG - - - - - - 12 16 20
Aspartame 10 10 10 10 10 10 10 10 10
Powder vanilla flavor 5 5 5 5 5 5 5 5 5
CA - - - - - - - - -
NaHCO3 - - - - - - - - -
SLS 4 4 4 4 4 4 4 4 4
Talc 6 6 6 6 6 6 6 6 6
Magnesium stearate 6 6 6 6 6 6 6 6 6
Mannitol 117 113 109 117 113 109 117 113 109
Total 200 200 200 200 200 200 200 200 200
*Quantity of ingredients per each tablet were expressed in Mg; average weight of a tablet is 200 mg. PH: Propranolol Hcl, ODT: Orally disintegrating tablet, CA: Citric 
Acid, CPV: Crospovidone, CCS: Croscarmellose sodium, SSG: Sodium starch glycolate, SLS: Sodium lauryl sulphate
Table 2: Formulation table of PH ODT with superdintegrents and effervescent mixture
%w/w superdisintegent 10% CPV 10% CCS 10% SSG
CA: NaHCO3 1:1 1:2 1:3 1:1 1:2 1:3 1:1 1:2 1:3
Ingredients* EF1 EF2 EF3 EF4 EF5 EF6 EF7 EF8 EF9
PH 40 40 40 40 40 40 40 40 40
CPV 20 20 20 - - - - - -
CCS - - - 20 20 20 - - -
SSG - - - - - - 20 20 20
Aspartame 10 10 10 10 10 10 10 10 10
Powder vanilla flavor 5 5 5 5 5 5 5 5 5
CA 10 10 10 10 10 10 10 10 10
NaHCO3 10 20 30 10 20 30 10 20 30
SLS 4 4 4 4 4 4 4 4 4
Talc 6 6 6 6 6 6 6 6 6
Magnesium stearate 6 6 6 6 6 6 6 6 6
Mannitol 89 79 69 89 79 69 89 79 69
Total 200 200 200 200 200 200 200 200 200
*Quantity of ingredients per each tablet was expressed in mg; average weight of a tablet is 200 mg. PH: Propranolol Hcl, ODT: Orally disintegrating tablet, CA: Citric acid, 
CPV: Crospovidone, CCS: Croscarmellose sodium, SSG: Sodium starch glycolate, SLS: Sodium lauryl sulphate
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4 minutes, the tablets were then de-dusted, reweighed, and percentage 
weight loss was calculated by the equation,
% friability= (initial weight-weight after friability) 
×100/initial weight (6)
Hardness test [12]
To evaluate the diametrical crushing strength, three tablets from 
each formulation were tested using a hardness tester (Monsanto type 
hardness tester, MHT-20, Campbell Electronics, India). The mean±SD 
values were calculated.
Thickness [12]
Of three tablets from each formulation was determined using a vernier 
caliper (Mitutoyo Corporation, Japan). The mean±SD values were 
calculated.
In vitro disintegration time and fineness of dispersion [13]
It is specified in the European Pharmacopeia (EP 6.0) that 
disintegration time determination procedure for ODT is same as 
that of conventional uncoated tablets and that the tablets should 
be dispersed within <3 minutes. The obtained tablet’s dispersion 
was passed through a sieve screen with a nominal mesh aperture of 
710 mm to confirm the fineness of dispersion. It was carried out in 
replicates of three tablets from each formulation and mean±SD values 
were calculated.
Wetting time and water absorption ratio [14]
A piece of tissue paper folded twice was placed in Petri dish having 
an internal diameter of 5.5 cm, containing 6 mL of water. A tablet was 
placed on the paper and the time required for complete wetting was 
measured as wetting time, using a stopwatch. The wetted tablet was 
then reweighed and water absorption ratio (R) was determined using 
following equation.
Water absorption ratio (R)=([Wa−Wb]/Wb)×100 (7)
Where, Wb and Wa were the weights of the tablet before and after water 
absorption.
Assay [9]
To evaluate the drug assay, three tablets from each formulation were 
powdered in motor and pestle. Blend equivalent to 1 mg of PLH was 
accurately weighed and transferred into a 100 mL volumetric flask. 
Then, the volume was made up to 100 mL with pH 6.8 phosphate 
buffer and ultra-sonicated for 2 minutes to extract the PLH from the 
tablet blend and filtered through 0.45 µm polytetrafluoroethylene 
(PTFE) filter disc, the filtrate was suitably diluted if necessary and its 
absorbance was measured by UV-visible spectrophotometer at 279 nm.
Postcompression studies of all the formulations, except friability 
test were carried out in triplicate (n=3); the consolidated results as 
(mean±SD) were tabulated in Table 4.
In vitro dissolution studies [9]
Were performed for three tablets form each formulation using the 
dissolution apparatus (Labindia Disso 2000, Labindia Analytical 
Instruments Pvt Ltd, India) with USP-II/paddle. Each dissolution 
flask contains 900 mL of pH 6.8 phosphate buffer; speed of the 
paddle was maintained at 50 rpm; the temperature was kept stable 
at 37°C±0.5°C. At required time intervals, 5 mL of dissolution media 
was withdrawn with a pipette containing 0.45 µ (PTFE) filter disc, 
suitably diluted if necessary and its absorbance was measured by 
UV-visible spectrophotometer at 279 nm. Furthermore, 5 mL of fresh 
pH 6.8 phosphate buffer was replaced to the dissolution flask to keep 
the volume of dissolution medium constant. The dissolution profiles 
were represented graphically in Fig. 3.
In vitro dissolution kinetics [15]
The in vitro drug release data were fitted into kinetic models to plot 
dissolution profiles (cum% drug dissolved versus time) and first 
order plots (log% drug undissolved versus time) as per the following 
equations.
Zero order: Qt=Q0+K0t (8)
First order: log Qt=log Q0−K1t/2.303  (9)
Where, Qt is the amount of the drug dissolved in time t, Q0 is the initial 
amount of drug in the solution; K0 and K1 refers to the rate constants of 
zero and first order, respectively.
In vitro dissolution kinetic parameters
Dissolution efficiency at 10 minutes (DE10) by trapezoid rule [16]; 
and time for 90% drug release (t90) were calculated from dissolution 




(C +C )(t -t )t1
t2
1 2 2 1   (10)
Table 3: Precompression studies of propranolol HCl ODT
F code Angle of repose (θ) BD (g/cm3) TD (g/cm3) Hausner’s ratio Carr’s index (%)
DC1 31.08 0.528 0.692 1.31 23.69
DC2 30.78 0.541 0.652 1.21 17.02
DC3 31.92 0.530 0.614 1.16 13.68
DC4 29.53 0.538 0.639 1.18 15.80
DC5 29.62 0.512 0.621 1.21 17.55
DC6 30.12 0.521 0.630 1.21 17.30
DC7 28.17 0.543 0.640 1.17 15.15
DC8 29.61 0.509 0.599 1.17 15.05
DC9 30.09 0.534 0.682 1.27 21.70
EF1 30.68 0.540 0.633 1.17 14.69
EF2 29.18 0.543 0.652 1.21 16.71
EF3 29.72 0.531 0.611 1.15 15.06
EF4 29.32 0.572 0.670 1.17 14.62
EF5 27.71 0.552 0.689 1.24 19.88
EF6 27.32 0.546 0.678 1.24 19.46
EF7 26.45 0.543 0.689 1.26 21.11
EF8 29.64 0.580 0.677 1.16 14.32
EF9 27.29 0.569 0.703 1.23 19.06
ODT: Orally disintegrating tablet, BD: Bulk density, TD: Tapped density
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Table 4: Postcompression studies of propranolol HCl ODT











DC1 0.202±2.97 2.8±0.24 3.5±0.24 0.74 50.00±0.01 98.02±0.30 6.21±0.61 94.24±0.97
DC2 0.205±0.97 2.9±0.16 3.5±0.48 0.66 44.66±1.21 90.12±1.53 9.41±0.02 95.68±0.48
DC3 0.202±0.99 2.7±0.24 3.5±0.48 0.49 42.66±1.77 89.16±0.90 13.82±0.53 95.47±0.12
DC4 0.204±1.47 2.9±0.12 3.4±0.97 0.49 58.66±1.10 117.20±1.33 6.53±1.12 94.24±0.44
DC5 0.201±0.99 2.8±0.12 3.5±0.24 0.49 54.66±2.21 115.5±2.08 8.11±1.55 95.68±0.16
DC6 0.207±0.48 2.9±0.16 3.5±0.97 0.66 54.25±1.10 102.34±0.88 11.66±0.77 96.47±0.48
DC7 0.202±1.98 2.9±0.16 3.4±0.79 0.80 59.66±1.10 121.22±2.5 3.41±0.01 95.29±0.12
DC8 0.204±2.45 2.7±0.24 3.5±0.48 0.82 56.33±0.87 117.23±1.15 4.86±0.99 95.29±0.44
DC9 0.203±1.47 2.8±0.24 3.5±0.48 0.40 56.12±2.21 113.09±2.10 5.87±1.44 94.66±1.12
EF1 0.206±1.60 2.6±0.16 3.5±0.48 0.25 16.66±1.12 26.33±0.44 23.31±2.42 96.40±0.44
EF2 0.202±1.68 2.7±0.24 3.5±0.24 0.49 13.33±0.88 22.00±1.33 23.71±0.71 97.73±1.12
EF3 0.206±0.97 2.7±0.24 3.5±0.48 0.41 11.00±1.12 13.66±1.11 25.39±5.12 96.57±0.48
EF4 0.206±0.58 2.7±0.24 3.5±0.79 0.41 16.00±0.66 29.66±0.88 19.36±1.02 95.69±1.11
EF5 0.208±1.25 2.8±0.24 3.5±0.48 0.33 19.00±0.66 28.24±0.66 21.35±2.45 95.21±1.12
EF6 0.202±1.13 2.9±0.16 3.4±0.48 0.33 20.32±0.88 27.00±1.33 22.59±2.93 96.02±0.12
EF7 0.204±0.78 2.6±0.16 3.5±0.97 0.49 24.31±1.11 37.00±1.33 18.45±1.34 98.72±0.16
EF8 0.202±0.79 2.7±0.24 3.5±0.79 0.49 23.00±0.66 35.66±0.44 20.74±2.25 94.88±0.66
EF9 0.204±0.58 2.8±0.24 3.5±0.79 0.66 26.33±0.44 34.66±1.78 21.24±1.13 97.57±0.66
*Except friability test all other were performed as n=3 and the values are given as mean±SD. ODT: Orally disintegrating tablet
Fig. 3: In vitro disso profiles of propranolol HCl orally disintegrating tablet (a) with crospovidone, (b) with croscarmellose sodium and 
(c) with sodium starch glycolate
a b
c





















t2  =Area under curve between time points t1 and t2
Total area at 10 minutes=10×100=1000 cm2
The first order dissolution rate constant (K1) and regression 
coefficient (r2) of the first order profiles were calculated from first 
order plots. The consolidated in vitro dissolution kinetic parameters of 
PLH ODT were tabulated in Table 5.
Accelerated stability studies [17]
Of the optimized formulation EF3, was carried out; by placing 20 tablets 
each in a 10 CC HDPE bottle; according to ICH guidelines in a humidity 
chamber (NSW-175, Narang Scientific Work, India) maintained at 
45°C±2°C and 75%±5% relative humidity up to 6 month. At the end 
of 1 month, 2 month, 3 month, and 6 month, the respective samples 
were withdrawn and evaluated for postcompression studies. The 
chemical stability of drug in the 6 month-accelerated stability sample 
of formulation EF3, was compared with the drug alone by FTIR studies 
(Shimadzu, FTIR 8700), recorded in the region of 400-4000/cm, by KBr 
pellet method. The consolidated results of postcompression studies 
on accelerated stability samples of formulation EF3; except friability 
test were carried out in triplicate and the results as mean±SD were 
tabulated in Table 6. FTIR spectra of pure PLH and 6 month-accelerated 
stability sample of formulation EF3 were represented in Fig. 4. In vitro 
dissolution profiles of accelerated stability samples of formulation EF3 
were represented graphically in Fig. 5.
RESULTS AND DISCUSSION
Standard calibration curve of PLH in pH 6.8 phosphate buffer
Based on the measurement of absorbance at 279 nm in pH 6.8 phosphate 
buffer in the concentration range of 10-50 µg/ml, a straight line with an 
equation: y=0.0193x+0.0151 and a regression coefficient (r2) of 0.9983 
was obtained (Fig. 1).
Drug-excipient compatibility/FTIR studies
The FTIR spectrum of PLH showed a characteristic secondary amine 
−NH stretch at 3280/cm, a C–H stretch at 2964/cm, an aryl C¼C stretch 
at 1579/cm, an aryl O–CH2 asymmetric stretch at 1240/cm, an aryl 
O–CH2 symmetric stretch at 1030/cm, and a peak at 798/cm due to 
alpha-substituted naphthalene. Comparison of FTIR spectra of pure 
drug with the drug: Superdisintegrant (1:1 ratio) samples indicate the 
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absence of chemical interaction between PLH and superdisintegrants 
used in the study (Fig. 2).
Precompression studies
Of the directly compressible blends of all formulations, reveals that the 
angle of repose was found between 26° 45’ and 31° 92’, BD between 
0.509 and 0.580 g/cm3, TD between 0.611 and 0.703 g/cm3, HR between 
1.15 and 1.31, and CI between 15.05% and 23.69%. The micromeritic 
studies indicate better flow and compression characteristics of all the 
formulations. In these formulations sugar based excipient (Mannitol) 
is used as diluent, which impart good flow and compressibility to 
the directly compressible blends. It also exhibits the high aqueous 
solubility and sweetness, and hence, impart taste masking property and 
a pleasing mouth feel [18] (Table 3).
Postcompression studies
Of all the formulations, reveals that the weight variation of tablets 
was found to be 0.201-0.208%. The average thickness of tablets was 
found to be 3.4-3.5 mm. The average hardness of the tablets was 
2.6-2.9 Kg/cm2, indicating satisfactory mechanical strength. The % 
weight loss in the friability test ranges from 0.25% to 0.82%, which 
was N-methyltryptamine 1% as per official requirement of Indian 
Pharmacopeia indicating a good mechanical strength of tablets. Assay of 
all the prepared batches is within 94.24-98.72% of the labeled content, 
indicating content uniformity of all the formulations. The wetting time of 
all the formulations was obtained in the range of 11.00-59.66 seconds. 
As the concentration of superdisintegrant increases, there is a 
significant decrease in the wetting time and in vitro disintegration time. 
Wetting is related to the inner structure of the tablets, hydrophilicity 
of the components and swelling mechanism of superdisintegrant. 
The water absorption ratio was related to the hydrophilicity of the 
matrix. This phenomenon was similar even with the combination 
of superdisintegrants with effervescent mixture in different ratios 
(1:1; 1:2, and 1:3). The order of superdisintegrant’s efficiency is 
CPV>CCS>SSG. The formulation EF3, (with 10% of CPV+1:3 ratio of 
citric acid: NaHCO3, respectively) which shows minutes wetting time 
of 11.00 seconds; minutes in vitro disintegration time of 13.66 seconds 
and max water absorption ratio of 25.39% is an optimized formulation 
(Table 4). Decrease in the wetting and disintegration times were clearly 
observed in formulations with a combination of superdisintegrants and 
effervescent mixture than the formulations with superdisintegrants 
alone. This is due to the synergistic effect of a combination of two 
approaches, namely superdisintegrants addition with effervescence 
approach. The evolved CO2 gas accelerated the breakdown of the 
tablets [19].
In vitro dissolution studies
Dissolution profiles are represented graphically in Figs. 1 and 2 indicate 
that the release rate increases with an increase in concentration 
of superdisintegrant. Based on the values of K1, the order of 
superdisintegrants in enhancing the dissolution rate of PLH in its ODT is 
(CPV>CCS>SSG). Formulations with a combination of superdisintegrants 
and effervescent mixture are having rapid disintegration and dissolution 
rate when compared to the formulations with superdisintegrants alone. 
A combination of two approaches, namely superdisintegrant addition with 
effervescence approach resulted in an increase in the drug dissolution 
rate, could be due to the synergistic effect of superdisintegrant and CO2 
produced due to the wetting of the tablets. The evolved gas accelerated 
the breakdown of the tablets as indicated by their lesser disintegration 
times [19]. Dissolution rate also enhances with an increase in citric acid: 
NaHCO3 ratio of effervescent mixture (1:1<1:2<1:3) as it requires three 
molecules of sodium bicarbonate to neutralize one molecule of citric acid. 
Hence, the desired ratio of citric acid: NaHCO3=1: 3.44 by weight [20]. 
Formulation EF3, (with 10% CPV AND 1:3, citric acid: NaHCO3 ratio, 
Table 6: Postcompression studies on accelerated stability samples of formulation EF3








Weight variation (%) 0.206±0.97 0.223±0.21 0.241±0.32 0.244±0.14 0.252±0.52
Hardness (kg/cm2) 2.7±0.24 2.6±0.12 2.6±0.35 2.5±0.12 2.5±0.33
Thickness (mm) 3.5±0.48 3.5±0.32 3.5±0.11 3.5±0.54 3.5±0.43
*Friability (%w/w) 0.41 0.43 0.51 0.53 0.50
Dissolution (seconds) 11.00±1.12 11.35±0.12 12.35±0.34 12.54±0.38 12.55±0.42
Wetting time (seconds) 13.66±1.11 14.12±0.13 14.76±0.32 14.23±0.45 14.52±0.21
Water absorption ratio (%) 25.39±5.12 25.78±0.15 26.23±0.22 27.35±0.42 27.11±0.35
Assay (%) 96.57±0.48 96.52±0.12 96.40±0.44 95.29±0.44 94.66±1.12
*Except friability test all other were performed as n=3 and the values are given as mean±SD. RH: Relative humidity
Table 5: In vitro dissolution kinetics of propranolol HCl ODT
F code t90 (minutes) DE10 (%) First order dissolution rate constant; K1 (minutes
−1) First order regression coefficient (r2)
DC1 18 46.35 0.110 0.667
DC2 16 50.40 0.113 0.652
DC3 14 53.44 0.118 0.653
DC4 >24 30.83 0.123 0.788
DC5 24 38.92 0.133 0.809
DC6 24 41.72 0.140 0.802
DC7 >24 29.97 0.127 0.908
DC8 >24 31.47 0.131 0.915
DC9 >24 34.64 0.149 0.927
EF1 6 80.00 0.129 0.973
EF2 6 81.84 0.136 0.979
EF3 4 82.74 0.141 0.974
EF4 8 75.39 0.074 0.993
EF5 8 76.32 0.086 0.969
EF6 6 77.86 0.094 0.966
EF7 14 68.83 0.064 0.935
EF8 14 69.89 0.068 0.982
EF9 10 71.92 0.080 0.993
ODT: Orally disintegrating tablet
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respectively) released 90% of drug within lesser time of 4 minutes than 
others, was considered as the optimal ODT (Fig. 3).
In vitro dissolution kinetics
Formulation EF3 had the highest DE10 (82.74%); K1 (0.141/minutes) 
with r2(0.974) and the lowest t90(4 minutes). Hence, it is the optimal 
ODT (Table 5).
Accelerated stability studies
As there were no significant differences in postcompression and in vitro 
dissolution profiles of initial and accelerated stability samples up to 
6 months, formulation, EF3 passes the test for stability. FTIR spectrum 
of pure PLH is having primary amide group and two secondary amino 
groups. Two N-H stretching bands resulting from symmetrical and 
asymmetrical stretching in 3400-3520/cm correspond to primary 
amide group [18]. An FTIR spectrum of 6 month-accelerated stability 
sample of optimized formulation (EF3) shows the same functional 
groups at the corresponding frequencies as that of pure drug. This, 
indicates no significant chemical interaction and change in functional 
groups of PLH occurred during the accelerated stability study of 
optimized formulation, EF3 (Table 6, Figs. 4 and 5).
CONCLUSION
In the view of above findings, there is drug-excipient compatibility 
between PLH and superdisintegrants used in the study. All the 
formulations passed the pre- and post-compression parameters. 
The release rate of PLH from ODT increases as the concentration 
of superdisintegrants as well as the ratio of citric acid: NaHCO3 of 
effervescent mixture increases. Formulations with an effervescent 
mixture are having rapid disintegration and dissolution rate when 
compared to the formulations with superdisintegrants alone. The 
order of superdisintegrants in enhancing the dissolution rate of PLH 
is CPV>CCS>SSG. Formulation EF3 (with 10% CPV and 1:3, citric 
acid: NaHCO3 ratio respectively) had the highest DE10 (82.74%); 
K1 (0.141/minutes) with r2 (0.974) and the lowest t90 (4 minutes), 
was considered as the optimal ODT. An accelerated stability study on 
EF3 in the final pack up to 6 months indicates it passed the test for 
stability. Therefore, an effective PLH ODT was formulated by the direct 
compression technique with disintegration attained by a combination 
of superdisintegrants and effervescent mixture. This PLH ODT will 
better manage the hypertension, by fastening the onset of action and 
enhancing the bioavailability of PLH in comparison to its conventional 
tablets.
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